Evolent Health Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Evolent Health stock.
View analyst ratings for Evolent Health or view top-rated stocks.

Wall Street analysts have given Evolent Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evolent Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Evolent Health is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Evolent Health.

Evolent Health, Inc. (NYSE:EVH) issued its earnings results on Thursday, February, 25th. The technology company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.09. Evolent Health had a negative net margin of 52.35% and a negative trailing twelve-month return on equity of 4.40%.
View Evolent Health's earnings history.

Evolent Health's stock was trading at $6.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EVH stock has increased by 176.2% and is now trading at $19.11.
View which stocks have been most impacted by COVID-19.

Evolent Health issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $830-880 million, compared to the consensus revenue estimate of $940.38 million.

10 analysts have issued 12-month target prices for Evolent Health's stock. Their forecasts range from $8.00 to $27.00. On average, they anticipate Evolent Health's share price to reach $18.00 in the next year. This suggests that the stock has a possible downside of 5.8%.
View analysts' price targets for Evolent Health or view top-rated stocks among Wall Street analysts.

12 employees have rated Evolent Health CEO Seth Blackley on Glassdoor.com. Seth Blackley has an approval rating of 100% among Evolent Health's employees. This puts Seth Blackley in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Evolent Health include Premier (PINC), ManTech International (MANT), Franklin Covey (FC), Jupai (JP), PHI Group (PHIL), Rainmaker Systems (VCTL) and Taylor Consulting (TAYO).
View all of EVH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Energy Transfer (ET), Chipotle Mexican Grill (CMG), Ford Motor (F), Cisco Systems (CSCO) and Heron Therapeutics (HRTX).

(EVH) raised $150 million in an initial public offering on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.53%), Credit Suisse AG (4.78%), Dimensional Fund Advisors LP (4.40%), Bank of New York Mellon Corp (2.35%), Glenmede Trust Co. NA (1.40%) and Nuveen Asset Management LLC (1.14%). Company insiders that own Evolent Health stock include Doug S Aron, Jonathan Weinberg, Kenneth A Samet, Michael D'amato and Seth Blackley.
View institutional ownership trends for Evolent Health.

EVH stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Voloridge Investment Management LLC, Glenmede Trust Co. NA, Royce & Associates LP, Peregrine Capital Management LLC, GSA Capital Partners LLP, Sei Investments Co., and State of Wisconsin Investment Board.
View insider buying and selling activity for Evolent Health or view top insider-selling stocks.

EVH stock was bought by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., Norges Bank, Credit Suisse AG, BlackRock Inc., First Trust Advisors LP, Guggenheim Capital LLC, Bank of New York Mellon Corp, and Truist Financial Corp. Company insiders that have bought Evolent Health stock in the last two years include Doug S Aron, Kenneth A Samet, Michael D'amato, and Seth Blackley.
View insider buying and selling activity for Evolent Health or or view top insider-buying stocks.

Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVH stock can currently be purchased for approximately $19.11.

Evolent Health has a market capitalization of $1.64 billion and generates $846.38 million in revenue each year. The technology company earns $-301,970,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

Evolent Health employs 3,400 workers across the globe.

The official website for Evolent Health is www.evolenthealth.com.

Evolent Health is headquartered at 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203.

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000 or via email at [email protected]